Matthew J. Frigault, MD

home / authors / matthew-j-frigault-md

Articles

Matthew Frigault, MD, discusses differences in the toxicities experienced with CAR T-cell products used in the treatment of patients with leukemias and lymphomas.

Dr. Frigault on Toxicity Differences Among CAR T-Cell Products in Leukemias, Lymphomas

Matthew J. Frigault, MD
January 11th 2021

Matthew Frigault, MD, discusses differences in the toxicities experienced with CAR T-cell products used in the treatment of patients with leukemias and lymphomas.

Read More

The Future of CAR T-Cell Therapy in Diffuse Large B-Cell Lymphoma

The Future of CAR T-Cell Therapy in Diffuse Large B-Cell Lymphoma

Matthew J. Frigault, MD
November 6th 2020

Read More

Impact of COVID-19 on CAR T-Cell Therapy for R/R DLBCL

Impact of COVID-19 on CAR T-Cell Therapy for R/R DLBCL

Matthew J. Frigault, MD
November 6th 2020

Read More

Real-World Data for CAR T-Cell Therapy for R/R DLBCL

Real-World Data for CAR T-Cell Therapy for R/R DLBCL

Matthew J. Frigault, MD
November 6th 2020

Read More

CAR T-Cell Therapy Clinical Trials for R/R DLBCL

CAR T-Cell Therapy Clinical Trials for R/R DLBCL

Matthew J. Frigault, MD
November 6th 2020

Read More

Mechanism of CAR T Cells in R/R Diffuse Large B-Cell Lymphoma

Mechanism of CAR T Cells in R/R Diffuse Large B-Cell Lymphoma

Matthew J. Frigault, MD
November 6th 2020

Read More

Overview of Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Overview of Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Matthew J. Frigault, MD
November 6th 2020

Read More

Latest Updated Articles

Sarwish Rafiq, PhD
Published: July 9th 2024 | Updated: July 10th 2024
Dr Rafiq on Novel Strategies for CAR T-Cell Engineering in Solid Tumors
Jens Hoeppner, FAChirg, FACS, MD
Published: June 2nd 2024 | Updated: June 3rd 2024
Perioperative Chemotherapy Prolongs OS vs Neoadjuvant Chemoradiation in Esophageal Cancer
Julia Rotow, MD, clinical director, Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute; assistant professor, medicine, Harvard Medical School
Published: July 25th 2024 | Updated: July 27th 2024
Dr Rotow on the Impact of Biomarker Testing on NSCLC Treatment Outcomes
Joshua K. Sabari, MD, assistant professor, Department of Medicine, New York University Grossman School of Medicine; director, High Reliability Organization Initiatives, Perlmutter Cancer Center
Published: July 25th 2024 | Updated: July 27th 2024
Dr Sabari on Barriers to Biomarker Testing in NSCLC
5 KOLs are featured in this series.
Published: July 18th 2024 | Updated: July 27th 2024
Treatment Considerations and Patient Selection for CAR T-cell Therapy in R/R ALL
5 KOLs are featured in this series.
Published: July 18th 2024 | Updated: July 27th 2024
Expert Insights on ZUMA-3 Data Updates: 4-Year Follow-up and Real World Data